Description
By 2010 many of the clinical trials presently underway targeting Abeta will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer s disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond Abeta as a key factor and therapeutic target in Alzheimer`s Disease. This objective will be equally important whether therapeutic approaches targeting Abeta are successful or not, to either complement and expand successful Abeta therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer`s Disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system, and protein degradation in Alzheimer`s Disease.
